(89)Zr-DFO-Cetuximab as a Molecular Imaging Agent to Identify Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma

Background: Despite the improvement in clinical outcomes for head and neck squamous cell carcinoma (HNSCC) as the result of cetuximab, patients may present with or develop resistance that increases tumor recurrence rates and limits clinical efficacy. Therefore, identifying those patients who are or...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Biother Radiopharm
Egile Nagusiak: Benedetto, Raquel, Massicano, Adriana V.F., Crenshaw, Bryant K., Oliveira, Renato, Reis, Rui M., Araújo, Elaine B., Lapi, Suzanne E.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Mary Ann Liebert, Inc., publishers 2019
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6588098/
https://ncbi.nlm.nih.gov/pubmed/30865493
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/cbr.2018.2616
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak